Search results
Results from the WOW.Com Content Network
Second-generation sulfonylureas have increased potency by weight, compared to first-generation sulfonylureas. [21] Similarly, ACCORD (Action to Control Cardiovascular Risk in Diabetes) [ 22 ] and the VADT (Veterans Affairs Diabetes Trial) [ 23 ] studies showed no reduction in heart attack or death in patients assigned to tight glucose control ...
The second-generation Chevrolet Camaro is an American pony car produced by Chevrolet from 1970 through the 1981 model years. It was introduced in the spring of 1970. [1] Build information for model 123-12487 [2] was released to the assembly plants in February of that same year. It was longer, lower, and wider than the first generation Camaro.
2 Sulfonylureas (anti-diabetic agents) 3 Diuretics. 4 Anticonvulsants. 5 Dermatologicals. 6 Antiretrovirals. 7 Hepatitis C antivirals. 8 Stimulants. 9 NSAIDs. 10 ...
It has a similar potency as glibenclamide (glyburide) in the class of medication known as sulfonylureas. Its structure is similar since it has a cyclic acyl group which replaces the latter's 2-methoxy-5-chlorobenzyl. [2] Same as glibenclamide, it is classified as a second-generation sulfonylurea.
It is classified as a second-generation sulfonylurea. [4] Glimepiride was patented in 1979 and approved for medical use in 1995. [5] It is available as a generic medication. [2] In 2022, it was the 64th most commonly prescribed medication in the United States, with more than 10 million prescriptions. [6] [7]
It's New for '67! Chevrolet unveiled the Camaro in September 1966. The car carried a base price of $2,466 (about $22,043 today) and offered a wide range of options, including a choice of 15 ...
The search engine that helps you find exactly what you're looking for. Find the most relevant information, video, images, and answers from all across the Web.
Chlorpropamide and other sulfonylureas encourage weight gain, so they are generally not favored for use in very obese patients. Metformin (Glucophage) is considered a better drug for these patients. Sulfonylureas should be used with caution or generally avoided in patients with hepatic and renal impairment, patients with porphyria , patients ...